129 related articles for article (PubMed ID: 28956343)
1. A Unique Sub-Pocket for Improvement of Selectivity of Phosphodiesterase Inhibitors in CNS.
Wang Y; Ke H
Adv Neurobiol; 2017; 17():463-471. PubMed ID: 28956343
[TBL] [Abstract][Full Text] [Related]
2. Structural basis for the activity of drugs that inhibit phosphodiesterases.
Card GL; England BP; Suzuki Y; Fong D; Powell B; Lee B; Luu C; Tabrizizad M; Gillette S; Ibrahim PN; Artis DR; Bollag G; Milburn MV; Kim SH; Schlessinger J; Zhang KY
Structure; 2004 Dec; 12(12):2233-47. PubMed ID: 15576036
[TBL] [Abstract][Full Text] [Related]
3. Crystal structures of phosphodiesterases 4 and 5 in complex with inhibitor 3-isobutyl-1-methylxanthine suggest a conformation determinant of inhibitor selectivity.
Huai Q; Liu Y; Francis SH; Corbin JD; Ke H
J Biol Chem; 2004 Mar; 279(13):13095-101. PubMed ID: 14668322
[TBL] [Abstract][Full Text] [Related]
4. Crystal structures of phosphodiesterases and implications on substrate specificity and inhibitor selectivity.
Ke H; Wang H
Curr Top Med Chem; 2007; 7(4):391-403. PubMed ID: 17305581
[TBL] [Abstract][Full Text] [Related]
5. Homology modeling, docking studies and molecular dynamic simulations using graphical processing unit architecture to probe the type-11 phosphodiesterase catalytic site: a computational approach for the rational design of selective inhibitors.
Cichero E; D'Ursi P; Moscatelli M; Bruno O; Orro A; Rotolo C; Milanesi L; Fossa P
Chem Biol Drug Des; 2013 Dec; 82(6):718-31. PubMed ID: 23865680
[TBL] [Abstract][Full Text] [Related]
6. Future directions in phosphodiesterase drug discovery.
DeNinno MP
Bioorg Med Chem Lett; 2012 Nov; 22(22):6794-800. PubMed ID: 23046962
[TBL] [Abstract][Full Text] [Related]
7. Crystal structure of the Leishmania major phosphodiesterase LmjPDEB1 and insight into the design of the parasite-selective inhibitors.
Wang H; Yan Z; Geng J; Kunz S; Seebeck T; Ke H
Mol Microbiol; 2007 Nov; 66(4):1029-38. PubMed ID: 17944832
[TBL] [Abstract][Full Text] [Related]
8. Use of structure based design to increase selectivity of pyridyl-cinnoline phosphodiesterase 10A (PDE10A) inhibitors against phosphodiesterase 3 (PDE3).
Hu E; Kunz RK; Rumfelt S; Andrews KL; Li C; Hitchcock SA; Lindstrom M; Treanor J
Bioorg Med Chem Lett; 2012 Nov; 22(22):6938-42. PubMed ID: 23044369
[TBL] [Abstract][Full Text] [Related]
9. A substrate selectivity and inhibitor design lesson from the PDE10-cAMP crystal structure: a computational study.
Lau JK; Li XB; Cheng YK
J Phys Chem B; 2010 Apr; 114(15):5154-60. PubMed ID: 20349929
[TBL] [Abstract][Full Text] [Related]
10. Phosphodiesterase inhibitors: factors that influence potency, selectivity, and action.
Francis SH; Houslay MD; Conti M
Handb Exp Pharmacol; 2011; (204):47-84. PubMed ID: 21695635
[TBL] [Abstract][Full Text] [Related]
11. Biological and structural characterization of Trypanosoma cruzi phosphodiesterase C and Implications for design of parasite selective inhibitors.
Wang H; Kunz S; Chen G; Seebeck T; Wan Y; Robinson H; Martinelli S; Ke H
J Biol Chem; 2012 Apr; 287(15):11788-97. PubMed ID: 22356915
[TBL] [Abstract][Full Text] [Related]
12. Selectivity mechanism of phosphodiesterase isoform inhibitor through in silico investigations.
Huang J; Hu B; Xu Z; Ye Y; Wang H; Wang S; Liu Z; Wang J
J Mol Model; 2021 Dec; 28(1):9. PubMed ID: 34907481
[TBL] [Abstract][Full Text] [Related]
13. BN/CC isosterism in borazaronaphthalenes towards phosphodiesterase 10A (PDE10A) inhibitors.
Vlasceanu A; Jessing M; Kilburn JP
Bioorg Med Chem; 2015 Aug; 23(15):4453-4461. PubMed ID: 26113188
[TBL] [Abstract][Full Text] [Related]
14. Interactions between cyclic nucleotide phosphodiesterase 11 catalytic site and substrates or tadalafil and role of a critical Gln-869 hydrogen bond.
Weeks JL; Corbin JD; Francis SH
J Pharmacol Exp Ther; 2009 Oct; 331(1):133-41. PubMed ID: 19641165
[TBL] [Abstract][Full Text] [Related]
15. Application of Free Energy Perturbation (FEP+) to Understanding Ligand Selectivity: A Case Study to Assess Selectivity Between Pairs of Phosphodiesterases (PDE's).
Moraca F; Negri A; de Oliveira C; Abel R
J Chem Inf Model; 2019 Jun; 59(6):2729-2740. PubMed ID: 31144815
[TBL] [Abstract][Full Text] [Related]
16. Autotaxin inhibition: development and application of computational tools to identify site-selective lead compounds.
Norman DD; Ibezim A; Scott WE; White S; Parrill AL; Baker DL
Bioorg Med Chem; 2013 Sep; 21(17):5548-60. PubMed ID: 23816044
[TBL] [Abstract][Full Text] [Related]
17. Structural determinants of phosphodiesterase 6 response on binding catalytic site inhibitors.
Simon A; Barabás P; Kardos J
Neurochem Int; 2006 Aug; 49(3):215-22. PubMed ID: 16519963
[TBL] [Abstract][Full Text] [Related]
18. PDEStrIAn: A Phosphodiesterase Structure and Ligand Interaction Annotated Database As a Tool for Structure-Based Drug Design.
Jansen C; Kooistra AJ; Kanev GK; Leurs R; de Esch IJ; de Graaf C
J Med Chem; 2016 Aug; 59(15):7029-65. PubMed ID: 26908025
[TBL] [Abstract][Full Text] [Related]
19. Radiolabeled ligand binding to the catalytic or allosteric sites of PDE5 and PDE11.
Weeks JL; Blount MA; Beasley A; Zoraghi R; Thomas MK; Sekhar KR; Corbin JD; Francis SH
Methods Mol Biol; 2005; 307():239-62. PubMed ID: 15988068
[TBL] [Abstract][Full Text] [Related]
20. N-Acylhydrazones as inhibitors of PDE10A.
Gage JL; Onrust R; Johnston D; Osnowski A; Macdonald W; Mitchell L; Urögdi L; Rohde A; Harbol K; Gragerov S; Dormán G; Wheeler T; Florio V; Cutshall NS
Bioorg Med Chem Lett; 2011 Jul; 21(14):4155-9. PubMed ID: 21696955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
